MX2023010992A - Composicion farmaceutica para mejorar la lesion pulmonar aguda y el empeoramiento agudo de la fibrosis pulmonar. - Google Patents
Composicion farmaceutica para mejorar la lesion pulmonar aguda y el empeoramiento agudo de la fibrosis pulmonar.Info
- Publication number
- MX2023010992A MX2023010992A MX2023010992A MX2023010992A MX2023010992A MX 2023010992 A MX2023010992 A MX 2023010992A MX 2023010992 A MX2023010992 A MX 2023010992A MX 2023010992 A MX2023010992 A MX 2023010992A MX 2023010992 A MX2023010992 A MX 2023010992A
- Authority
- MX
- Mexico
- Prior art keywords
- acute
- pharmaceutical composition
- pulmonary fibrosis
- lung injury
- ameliorating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021046301 | 2021-03-19 | ||
| JP2021173381 | 2021-10-22 | ||
| PCT/JP2022/012823 WO2022196816A1 (ja) | 2021-03-19 | 2022-03-18 | 急性肺障害および肺線維症の急性増悪を改善するための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010992A true MX2023010992A (es) | 2023-11-14 |
Family
ID=83320552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010992A MX2023010992A (es) | 2021-03-19 | 2022-03-18 | Composicion farmaceutica para mejorar la lesion pulmonar aguda y el empeoramiento agudo de la fibrosis pulmonar. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260116957A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4310099A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022196816A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230171941A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022239051A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214262A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023010992A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022196816A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116570716B (zh) * | 2023-04-28 | 2025-05-16 | 水木星辰生物制药(深圳)有限公司 | lncRNA LOC646762表达的抑制剂的应用和药物 |
| CN117327147B (zh) * | 2023-09-26 | 2024-05-10 | 广东海洋大学 | 一种抗急性肺损伤多肽及其应用 |
| WO2026134246A1 (ja) * | 2024-12-18 | 2026-06-25 | 国立大学法人三重大学 | Corisin発現非ヒト動物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9622660D0 (en) * | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
| WO2014089209A2 (en) * | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| JP6394441B2 (ja) * | 2014-04-07 | 2018-09-26 | 株式会社デンソー | 内燃機関の冷却装置 |
| US10280223B2 (en) * | 2014-07-09 | 2019-05-07 | Nippon Zenyaku Kogyo Co., Ltd. | Anti-canine PD-1 antibody or anti-canine PD-L1 antibody |
| EP3380521A1 (en) * | 2015-11-24 | 2018-10-03 | Eli Lilly and Company | Combination therapy for cancer |
| WO2017214456A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| EP3678717B1 (en) * | 2017-09-04 | 2026-07-08 | Wockhardt Limited | Autoinjector with a needle cover |
| EP3629024A1 (en) * | 2018-09-26 | 2020-04-01 | Assistance Publique - Hôpitaux de Marseille | Cd146 and uses thereof as a biomarker and as a therapeutic target in the diagnosis and treatment of fibrosis |
| EP3689373A1 (en) * | 2019-01-30 | 2020-08-05 | IDT Biologika GmbH | Inactivated apxia, apxiia and apxiiia toxins |
| JP2021046301A (ja) | 2019-09-19 | 2021-03-25 | 株式会社Screenホールディングス | フィルムの剥離装置及び、フィルムの剥離方法 |
| US11723926B2 (en) * | 2019-09-27 | 2023-08-15 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| US20230357373A1 (en) * | 2019-12-17 | 2023-11-09 | Mie University | Methods and compositions for evaluating and treating fibrosis |
| JP2021173381A (ja) | 2020-04-28 | 2021-11-01 | トヨタ自動車株式会社 | ファンカップリング装置の制御装置 |
-
2022
- 2022-03-18 JP JP2023507207A patent/JPWO2022196816A1/ja active Pending
- 2022-03-18 KR KR1020237035872A patent/KR20230171941A/ko active Pending
- 2022-03-18 WO PCT/JP2022/012823 patent/WO2022196816A1/ja not_active Ceased
- 2022-03-18 CA CA3214262A patent/CA3214262A1/en active Pending
- 2022-03-18 US US18/282,975 patent/US20260116957A1/en active Pending
- 2022-03-18 AU AU2022239051A patent/AU2022239051A1/en active Pending
- 2022-03-18 MX MX2023010992A patent/MX2023010992A/es unknown
- 2022-03-18 EP EP22771559.6A patent/EP4310099A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260116957A1 (en) | 2026-04-30 |
| EP4310099A1 (en) | 2024-01-24 |
| JPWO2022196816A1 (cg-RX-API-DMAC7.html) | 2022-09-22 |
| AU2022239051A9 (en) | 2023-10-26 |
| AU2022239051A1 (en) | 2023-10-12 |
| WO2022196816A1 (ja) | 2022-09-22 |
| KR20230171941A (ko) | 2023-12-21 |
| CA3214262A1 (en) | 2022-09-22 |
| EP4310099A4 (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| MX2017011615A (es) | Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1. | |
| ZA202004980B (en) | A modified raav capsid protein for gene therapy | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| MX2019012445A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| CO2018011933A2 (es) | Derivados de piridiniltriazol sustituidos con amida y usos de estos | |
| CY1124943T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν rpl554 σε hfa-134a για χορηγηση με εισπνοη | |
| WO2016200543A8 (en) | Aav-mediated expression of anti-influenza antibodies and methods of use thereof | |
| MX2023006471A (es) | Composiciones farmaceuticas mejoradas que contienen vector viral adenoasociado. | |
| EA202092678A1 (ru) | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон | |
| EA202190960A1 (ru) | Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30) | |
| MX2022013963A (es) | Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas. | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| MY195945A (en) | Ras Protein Degradation Inducing Molecule and Pharmaceutical Composition | |
| MX2009003638A (es) | Tensioactivos reconstituidos que tienen propiedades mejoradas. | |
| ZA202107826B (en) | Pharmaceutical parenteral composition of dual glp1/2 agonist | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| WO2019036725A3 (en) | PEPTIDE INHIBITORS OF TAU AGGREGATION | |
| BR112017028137A2 (pt) | agente terapêutico para fibrose | |
| CL2023000200A1 (es) | Nuevo derivado de pirazol | |
| BRPI0414868A (pt) | composições e métodos compreendendo compostos relacionados com prostaglandina e peptìdios da famìlia do fator trifoliado para o tratamento de glaucoma com hiperemia reduzida | |
| MA38369B1 (fr) | Peptides et compositions pour le traitement d'une lesion de l'articulation | |
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| WO2023150618A3 (en) | Conjugated hepcidin mimetics |